October 2014 Issue of The Medicine Maker

Our understanding of the differences in male and female biology is constantly growing – but can we translate that knowledge into better healthcare for all?

“Welcome to Big Pharma, where you can make a fortune and still maintain a healthy conscience. Or can you?”

A business simulation video game called Big Pharma is being made by a UK game studio called Twice Circled.

Merck KGaA snaps up Sigma-Aldrich, Allergan fights Valeant, and Shire–Abbvie deal sours

New NIH policies aim to correct the sex bias in preclinical research.

Opportunistic investors surf the wave of experimental treatments

New Alzheimer’s treatment gets $500 million collaborative boost

Mysterious cyber attackers are hitting pharma manufacturing systems

Quick fire Q&A with Hans-Georg Eichler, Senior Medical Officer, EMA

Organizations all over the globe are taking action against drug resistance.

The US is finally introducing regulation on drug serialization and traceability, but gaps remain that could leave patients vulnerable.

Many drug developers are going ‘full steam ahead’ with personalized medicine strategies.

It is clear that terminal sterilization is the gold standard for sterile drug manufacture, so why are companies so reluctant to pursue it?

Patients and physicians are tweeting, snapchatting, pinning and posting about healthcare, – some are making the leap into the digital world.

If I knew six years ago just how much of my time EXCiPACT would take up, would I have even started?

In a world of regulatory rigor and complex supply chains, product recalls are becoming increasingly challenging.

With an EMA pilot scheme underway it looks likely that adaptive licensing will feature in the future drug development landscape.

The rise of drug resistance has left us facing a future with few effective antibiotics. Do the next-generation antibiotics in the pipeline offer hope?

Hiring gifted new employees is tough enough, but how do you keep them within your organization once you’ve got them?

Sitting Down With… Nick Haggar, Head of Western Europe, Middle East & Africa, Sandoz, and President of the European Generic Medicines Association (EGA).